Readoutin 14d
Karyopharm Therapeutics Inc — Selinexor (combination therapy)
Phase 3 primary completion: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Relapsed/Refractory Diffuse Large B-cell Lymphoma